Orforglipron vs Thymagen
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
OrforglipronImmune Support
Thymagen- Summary
- Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
- Thymagen is a dipeptide bioregulator (Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the thymus gland. It supports T-lymphocyte maturation, thymic function, and immune system normalization. As the thymus involutes with age (thymic atrophy), immune competence declines. Thymagen is used to support immune restoration, particularly in aging, post-illness recovery, and immunodeficiency states.
- Half-Life
- ~12 hours (once-daily oral dosing)
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- Oral
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 12 mg → 24 mg → 36 mg → 45 mg
- 10 mg per day
- Frequency
- Once daily
- Daily for 10–30 days
- Key Benefits
- Oral pill — no injections required
- Once-daily dosing without food restrictions (unlike oral semaglutide)
- Up to 9.4% body weight reduction in Phase 2 at 36 weeks
- Significant HbA1c reduction in type 2 diabetes trials
- Small-molecule stability — no cold chain requirements
- Broadens access for injection-averse patients
- Potential class-defining convenience advantage over injectable GLP-1s
- Supports thymic epithelial cell function and T-cell maturation
- May partially restore thymic output reduced by age-related atrophy
- Normalizes T-lymphocyte subpopulation balance
- Supports immune recovery after illness, surgery, or chemotherapy
- Anti-aging effects on thymic tissue
- Complementary to Thymosin Alpha-1 and Thymalin in immune protocols
- May improve vaccine responsiveness in older individuals
- Side Effects
- Nausea (most common, dose-dependent)
- Vomiting
- Diarrhea
- Decreased appetite
- +2 more
- Generally well tolerated
- Mild injection site reactions
- No significant immunological adverse events reported
- Stacks With
- —
- —